88 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Jagiellonian University Medical College
Rational design of dual peptides targeting ghrelin and Y2 receptors to regulate food intake and body weight.
Universit£T Leipzig
Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications.
University of Copenhagen
Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.
University of Regensburg
Replacement of Thr32 and Gln34 in the C-terminal neuropeptide Y fragment 25-36 by cis-cyclobutane and cis-cyclopentane β-amino acids shifts selectivity toward the Y(4) receptor.
University of Regensburg
The discovery of potent selective NPY Y(2) antagonists.
Janssen Research and Development
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
Institute of Organic Synthesis
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
Universit£
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Broad Institute of Mit and Harvard
The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.
Glaxosmithkline
Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor antagonists.
The Scripps Research Institute
Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
Aska Pharmaceutical
Discovery of novel orally active ureido NPY Y5 receptor antagonists.
Schering-Plough Research Institute
Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands.
Salk Institute
Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.
Lundbeck Research Usa
The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y2 receptor.
Johnson & Johnson Pharmaceutical Research & Development
Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.
Tsukuba Research Institute
Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.
Universit£T Regensburg
Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists.
Pfizer
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical and Public Health Institute
Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.
Glaxosmithkline
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
Università
Discovery and SAR of cyclic isothioureas as novel NPY Y1 receptor antagonists.
Schering-Plough Research Institute
[Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging.
Universit£
Identification of positron emission tomography ligands for NPY Y5 receptors in the brain.
Tsukuba Research Institute
Synthesis and evaluation of a series of 2,4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors.
Tsukuba Research Institute
Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists.
Tsukuba Research Institute
The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.
Glaxosmithkline
8-amino-6-(arylsulphonyl)-5-nitroquinolines: novel nonpeptide neuropeptide Y1 receptor antagonists
TBA
Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.
Tsukuba Research Institute
Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.
Tsukuba Research Institute
Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.
University of Regensburg
Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
Banyu Tsukuba Research Institute
Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
Banyu Tsukuba Research Institute
(9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.
Tsukuba Research Institute
Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice.
Bayer Pharmaceuticals
A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice.
Bayer Pharmaceuticals
Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity.
University of Cincinnati
N-Terminus to Arginine Side-Chain Cyclization of Linear Peptidic Neuropeptide Y Y
University of Regensburg
Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists.
Novartis Pharma
Novel non-peptidic neuropeptide Y Y2 receptor antagonists.
Johnson & Johnson Pharmaceutical Research and Development
Differentially functionalized diamines as novel ligands for the NPY2 receptor.
Bristol-Myers Squibb Pharmaceutical Research Institute
Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.
Syracuse University
Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-Hormonal Treatment for Obesity.
The Scripps Research Institute
Synthesis and structure-activity relationships of trisubstituted phenyl urea derivatives as neuropeptide Y5 receptor antagonists.
Amgen
Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90).
University of Cincinnati and Va Medical Centers
High Affinity Agonists of the Neuropeptide Y (NPY) Y4 Receptor Derived from the C-Terminal Pentapeptide of Human Pancreatic Polypeptide (hPP): Synthesis, Stereochemical Discrimination, and Radiolabeling.
University of Regensburg
Structure-activity studies including a Psi(CH(2)-NH) scan of peptide YY (PYY) active site, PYY(22-36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine.
University of Cincinnati Medical Center
Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.
University of Regensburg
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.
Novartis Pharma
Pharmacological treatment of obesity: therapeutic strategies.
The R. W. Johnson Pharmaceutical Research Institute
Bis(31/31') ([CYS(31), Trp(32), Nva(34)] NPY-(31-36)): a specific NPY Y-1 receptor antagonist.
University of Cincinnati Medical Center
N(?)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.
Cnrs/Ipbs (Institut De Pharmacologie Et Biologie Structurale)
Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues.
Salk Institute
Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.
Salk Institute
Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y2-type receptors and potent functional antagonism at a Y1-type receptor.
Burroughs Wellcome
Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives.
Takeda Pharmaceutical
Highly potent antiobesity effect of a short-length peptide YY analog in mice.
Takeda Pharmaceutical
Identification and biological evaluation of thiazole-based inverse agonists of ROR?t.
Phenex Pharmaceuticals
Potent antiobesity effect of a short-length peptide YY-analogue continuously administered in mice.
Takeda Pharmaceutical
Antiobesity Effect of a Short-Length Peptide YY Analogue after Continuous Administration in Mice.
Takeda Pharmaceutical
A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance.
Massachusetts Institute of Technology
Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease.
Yogi Vemana University